Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early
adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for
patients who are potentially cured by radical prostatectomy but who are at high risk for
relapse. The standard of care is surveillance, with the addition of androgen deprivation at
the time of biochemical relapse. This study will assess the effect of adding early
chemotherapy to the standard of care on progression free survival in Veterans at high risk
for progression after prostatectomy.